Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of StreptInCor Vaccine in Healthy Adults
NCT07078357Phase 2Not yet recruiting
- Sponsor
- Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
- Start
- Oct 2025
- Primary completion
- Oct 2027
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of StreptInCor in Streptococcus pyogenes infection, rheumatic heart disease (RHD), sponsored by Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
StreptInCor
03
Conditions
Streptococcus pyogenes infectionrheumatic heart disease (RHD)
Beyond the preview
Go deeper on NCT07078357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07078357.